pet care
Experts Agree: Pet Health Earnings Beat Zoetis-Elanco Wins
Elanco’s Q1 2026 earnings beat because its EPS of $2.75 per share reflects higher veterinary drug sales, margin expansion and strategic reinvestment in pet health, giving investors a clear advantage over Zoetis and Boehringer. The surge signals stronger cash flow for innovative therapies and safety solutions. Elanco posted